Dapu Biopharmaceutical

Dapu Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of mRNA-based vaccines and therapeutics. Founded by industry veterans with extensive experience at global pharmaceutical firms like GSK and Novartis, the company has established a proprietary mRNA platform that integrates sequence optimization, delivery systems, and large-scale GMP manufacturing. Its lead program, DP-001, is an mRNA vaccine candidate for COVID-19 that has progressed into Phase 2 clinical trials. Beyond infectious diseases, Dapu Bio is expanding its pipeline into oncology and other therapeutic areas where mRNA technology can provide innovative solutions. The company is backed by prominent investors including Hillhouse Capital and Shenzhen Capital Group.